Leuprorelin depot - Camurus

Drug Profile

Leuprorelin depot - Camurus

Alternative Names: CAM 2032; Leuprolide Acetate FluidCrystal® Injection Depot; Prozenze

Latest Information Update: 22 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Camurus
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 22 Jun 2016 Leuprorelin depot - Camurus is available for licensing as of 21 Jun 2016. http://www.camurus.com/
  • 21 Jun 2016 Pharmacokinetics and adverse events data from a phase II clinical trial in Prostate cancer released by Camurus
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top